Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EXCILE-HF: Ivabradine and exercise tolerance in chronic heart failure
jRCTs031200281Completed
- Sponsor
- Ono Pharmaceutical
- Start
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of ivabradine in chronic heart failure (CHF) (2 arms), sponsored by Ono Pharmaceutical. Primary endpoint: Change in peak VO2 from baseline to 12 weeks. Started Apr 2021; status: completed.
02
Drugs
ivabradine
03
Conditions
chronic heart failure (CHF)
Beyond the preview
Go deeper on jRCTs031200281.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031200281.